ArticleJournal of advanced research2026
ZUP1 promotes DNA repair and immune evasion to drive olaparib resistance in triple-negative breast cancer.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rapid relapse in triple-negative breast cancer: clinical patterns, platinum resistance, and implications for clonal evolution.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOlaparib resistance limits its therapeutic efficacy in triple-negative breast cancer (TNBC). Exploring the mechanisms underlying olaparib resistance and developing combination strategies are of great clinical significance for improving the long-term therapeutic benefit in TNBC.
objectivesThis study aimed to determine whether ZUP1 is associated with olaparib resistance in TNBC patients and to elucidate the underlying mechanisms involved.
methodsWe established an olaparib-resistant TNBC cell model and integrated transcriptomic profiling with public datasets to DUBs linked to resistance. Candidate function was assessed by drug sensitivity assay, clonogenic assay, apoptosis assay, HR/NHEJ reporter assays and comet assays. Mechanistic studies used co-immunoprecipitation, chromatin fractionation, and PARylation assays. In vitro co-culture assays and flow cytometry analysis were used to evaluated immune infiltration. High-throughput virtual screening (HTVS), biolayer interferometry (BLI), and deubiquitination assays nominated small molecule inhibitors and assessed therapeutic synergy with olaparib.
resultsWe identified ZUP1, a recently uncovered deubiquitinase, as significantly upregulated in TNBC patients who did not respond to olaparib. Mechanistically, ZUP1 stabilized PARP1 by removing its polyubiquitin chains at lysine 425, resulting in increased PARylation and enhanced chromatin retention of SSRP1 and SPT16, thereby promoting DNA repair. ZUP1 deficiency significantly increased olaparib-induced DNA damage, facilitates cytosolic dsDNA release to activate STING signalling, and enhanced CD8
conclusionZUP1 facilitates olaparib resistance in TNBC by stabilizing PARP1 and enhancing DNA damage repair. Pharmacological inhibition of ZUP1 with procyanidin C1 represents a promising therapeutic strategy to overcome olaparib resistance in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.